Zinc transporter 8 autoantibody testing requires age-related cut-offs
Introduction Zinc transporter 8 autoantibodies (ZnT8A) are biomarkers of beta cell autoimmunity in type 1 diabetes that have become more widely available to clinicians in recent years. Robust control population-defined thresholds are essential to ensure high clinical specificity in islet autoantibod...
Main Authors: | Angus G Jones, Timothy James McDonald, Angela Cooper, Sian Louise Grace |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-08-01
|
Series: | BMJ Open Diabetes Research & Care |
Online Access: | https://drc.bmj.com/content/9/1/e002296.full |
Similar Items
-
Zinc transporter 8 autoantibody in the diagnosis of type 1 diabetes in children
by: Nur Rochmah, et al.
Published: (2020-10-01) -
Autoimmune thyroid disease correlates to islet autoimmunity on zinc transporter 8 autoantibody
by: Yun Cai, et al.
Published: (2021-05-01) -
Importance of Zinc Transporter 8 Autoantibody in the Diagnosis of Type 1 Diabetes in Latin Americans
by: Karla Fabiana Brasil Gomes, et al.
Published: (2017-03-01) -
Zinc transporter 8 (ZnT8) autoantibody prevalence in black South African participants with type 1 diabetes
by: Sureka Bhola, et al.
Published: (2021-07-01) -
Zinc transporter-8 autoantibodies can replace IA-2 autoantibodies as a serological marker for juvenile onset type 1 diabetes in India
by: C Shivaprasad, et al.
Published: (2014-01-01)